The FDA has issued new safety guidelines for systemic fluoroquinolones, restricting their use to patients with no alternative treatment options…
Roche & Novartis Face Off in Biosimilar Drug Battle
ZURICH (Reuters)—Switzerland’s biggest drugmakers are clashing over cheaper copies of pricey biotech drugs—one reason why Novartis is considering selling its $14 billion stake in cross-town rival Roche. With a copycat of Roche’s blood cancer drug Rituxan (rituximab) pending European approval, Novartis aims to muscle in on a share of sales that last year hit 7…
Inflammation May Sensitize Patients with Osteoarthritis to Pain
A recent editorial in Arthritis & Rheumatology explored the role of sensitization, not nociception, as a key mechanism of pain for patients with knee OA, as well as inflammation’s role in pain perception. Recent research of synovitis and joint effusion supports the idea that early prevention or treatment of sensitization may be paramount to reducing long-term pain in patients with knee OA…
Massage May Be an Option for Pain Relief
(Reuters Health)—Massage is better than nothing for pain relief, according to a new review. The therapy may also be an acceptable choice for people considering other options, such as acupuncture and physical therapy. “It should be considered at least for musculoskeletal pain as a viable option in the mix of pain management techniques in these areas,”…
Lilly Says New Type of Pain Drug Could Reduce Need for Opioids
(Reuters)—Eli Lilly and Co. on Tuesday said it and partner Pfizer Inc. aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain. The Indianapolis drugmaker said tanezumab, given by injection every eight weeks, could be a far…
Not Junk Mail: Social Security Letter Can Cut Medicare Costs
CHICAGO (Reuters)—A letter arrives in the mail with this opening line: “We are writing to let you know how you can get help paying your Medicare costs.” Your fraud detector probably goes on high alert—the mailboxes of retirees routinely are stuffed with bogus come-ons. But this letter is no scam. More than 2 million seniors…
U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction
(Reuters)—The first-ever implant to fight addiction to opioids, a class of drugs that includes prescription painkillers and heroin, was approved by the U.S. Food and Drug Administration on Thursday. The matchstick-sized implant, developed by Titan Pharmaceuticals Inc. and privately owned Braeburn Pharmaceuticals, is by design less susceptible to abuse or the illicit resale that plagues…
Rheumatology & Other Medical Residents Have High Risk of Depression
Over the past 40 years, the prevalence and risk of depression for medical residents has increased, according to research from Douglas A. Mata, MD, MPH, and colleagues. Addressing this phenomenon may be vital for the future of rheumatology and medicine…
Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain
Recent clinical trials have evaluated the efficacy of GSK3196165, a monoclonal antibody, and fasinumab, a nerve growth factor antibody, in treating patients with osteoarthritis and pain…
Doubts Mount over Merger of Health Insurers Anthem, Cigna
(Reuters)—Wall Street expressed growing doubts about a pending $54 billion merger of U.S. health insurers Anthem Inc. and Cigna Corp. on Monday as news of management squabbles added to concerns over its review by antitrust regulators. Cigna shares closed down 4% at $126.15, well below Anthem’s original $188 per share offer of cash and stock…
- « Previous Page
- 1
- …
- 502
- 503
- 504
- 505
- 506
- …
- 816
- Next Page »